Yazar "Min, Y. J." seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial(Oxford Univ Press, 2018) Goss, G. D.; Cobo, M.; Lu, S.; Syrigos, K.; Lee, K. H.; Goker, E.; Georgoulias, V.; Li, W.; Isla, D.; Morabito, A.; Min, Y. J.; Ardizzoni, A.; Cseh, A.; Bender, S.; Felip, E.Öğe Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung(Oxford Univ Press, 2016) Goss, G.; Lee, K. H.; Felip, E.; Cobo, M.; Syrigos, K.; Goker, E.; Georgioulias, V.; Guclu, S. Z.; Isla, D.; Min, Y. J.; Morabito, A.; Dupuis, N.; Chand, V. K.; Solca, F.; Kraemer, N.; Gibson, N.; Ehrnrooth, E.; Soria, J. C.
